Abstract
Background Activating mutations affecting exon 3 of the β-catenin (CTNNB1) gene result in constitutive activation of WNT signaling and are a diagnostic hallmark of several tumor entities including desmoid-type fibromatosis. They also define clinically relevant tumor subtypes within certain entities such as endometrioid carcinoma. In diagnostics, β-catenin immunohistochemistry is widely used as a surrogate for CTNNB1 mutations, but is often difficult to assess in practice, given that the characteristic nuclear translocation may be focal or hard to distinguish from spillover of the normal membranous staining.
Study design and methods We therefore examined Lymphoid Enhancer-Binding Factor 1 (LEF1) immunostaining, a nuclear marker of WNT activation that serves as a potential surrogate of CTNNB1 mutations.
Results In a cohort of endometrial carcinomas (n=255) LEF1 predicted CTNNB1 mutations correctly in 85%, while β-catenin was 76% accurate. Across a variety of entities characterized by CTNNB1 mutations as putative drivers, we found diffuse and strong expression of LEF1 in 77% of cases. LEF1 immunostaining proved easier to interpret than β-catenin immunostaining in 54% of cases, more difficult in 1% of cases, and comparable in the remaining cases.
Conclusion We conclude that LEF1 immunostaining is a useful surrogate marker for CTNNB1 mutations. It favorably complements β-catenin immunohistochemistry and outperforms the latter as a single marker.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Bernese Cancer League and the Bernese foundation of clinical-experimental tumour research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was performed in accordance with the Swiss Federal Act on Research involving Human Beings and with approval of the Ethics Commission of the Canton of Bern (KEK 2014-200 and 2017-1189).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest: The authors declare that they have no conflict of interest.
Extended molecular characterization Updated References
Data Availability
All data produced in the present study are available upon reasonable request to the authors
